104 related articles for article (PubMed ID: 2108838)
41. Alterations in bone marrow and blood mononuclear cell polyamine and methylglyoxal bis(guanylhydrazone) levels: phase I evaluation of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) treatment of human hematological malignancies.
Maddox AM; Freireich EJ; Keating MJ; Haddox MK
Cancer Res; 1988 Mar; 48(5):1367-73. PubMed ID: 3124958
[TBL] [Abstract][Full Text] [Related]
42. Alpha-difluoromethylornithine-induced inhibition of growth of autochthonous experimental colonic tumors produced by azoxymethane in male F344 rats.
Zhang SZ; Luk GD; Hamilton SR
Cancer Res; 1988 Nov; 48(22):6498-503. PubMed ID: 3141045
[TBL] [Abstract][Full Text] [Related]
43. Effect of cyclophosphamide on leukocytic subset distributions in rats carrying the Dunning R3327-MAT-LyLu prostatic adenocarcinoma.
Shaw MW; Rubenstein M; Dubin A; McKiel CF; Guinan PD
Prostate; 1987; 11(2):117-25. PubMed ID: 2959910
[TBL] [Abstract][Full Text] [Related]
44. Chemoprevention of oral carcinogenesis by DL-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquinoline 1-oxide-induced tongue neoplasms in rats.
Tanaka T; Kojima T; Hara A; Sawada H; Mori H
Cancer Res; 1993 Feb; 53(4):772-6. PubMed ID: 8428357
[TBL] [Abstract][Full Text] [Related]
45. Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice.
Sunkara PS; Rosenberger AL
Cancer Res; 1987 Feb; 47(4):933-5. PubMed ID: 3100031
[TBL] [Abstract][Full Text] [Related]
46. Effects of cyclosporin A and alpha-difluoromethylornithine on the growth of hamster pancreatic cancer in vitro.
Saydjari R; Townsend CM; Barranco SC; James E; Thompson JC
J Natl Cancer Inst; 1986 Nov; 77(5):1087-92. PubMed ID: 3022056
[TBL] [Abstract][Full Text] [Related]
47. Polyamine deprivation: a new tool in cancer treatment.
Quemener V; Blanchard Y; Chamaillard L; Havouis R; Cipolla B; Moulinoux JP
Anticancer Res; 1994; 14(2A):443-8. PubMed ID: 8017845
[TBL] [Abstract][Full Text] [Related]
48. Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma.
Mickey DD; Carvalho L; Foulkes K
Prostate; 1989; 15(3):221-32. PubMed ID: 2511562
[TBL] [Abstract][Full Text] [Related]
49. Phase I-II clinical trial with alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Horn Y; Schechter PJ; Marton LJ
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1103-7. PubMed ID: 3115786
[TBL] [Abstract][Full Text] [Related]
50. Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro.
Barranco SC; Townsend CM; Ho BY; Reumont KJ; Koester SK; Ford PJ
Invest New Drugs; 1990; 8 Suppl 1():S9-18. PubMed ID: 1696247
[TBL] [Abstract][Full Text] [Related]
51. Influence of cyclosporin A and alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on two rodent T-cell cancers in vivo.
Smart LM; MacLachlan G; Wallace HM; Thomson AW
Int J Cancer; 1989 Dec; 44(6):1069-73. PubMed ID: 2514149
[TBL] [Abstract][Full Text] [Related]
52. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats.
Rosenberg CA; Hrushesky WJ; Langevin T; Kennedy BJ
Oncology; 1985; 42(1):48-54. PubMed ID: 3969257
[TBL] [Abstract][Full Text] [Related]
53. [The involvement of polyamines in the malignant proliferative process. The anticancer effect of polyamine deprivation].
Quemener V; Chamaillard L; Brachet P; Havouis R; Moulinoux JP
Ann Gastroenterol Hepatol (Paris); 1995; 31(3):181-8; discussion 188-9. PubMed ID: 7653990
[TBL] [Abstract][Full Text] [Related]
54. Growth inhibition of a prostate tumor by alpha-difluoromethylornithine and by cyclophosphamide.
Heston WD; Kadmon D; Fair WR
Cancer Lett; 1982; 16(1):71-79. PubMed ID: 6811130
[TBL] [Abstract][Full Text] [Related]
55. Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma.
Mickey DD; Carvalho L; Foulkes K
J Urol; 1989 Dec; 142(6):1594-8. PubMed ID: 2585643
[TBL] [Abstract][Full Text] [Related]
56. The effect of low-dose cyclophosphamide and immunologic exposure upon growth of established Dunning R-3327-G subline rat prostate adenocarcinomas.
Rubenstein M; Shaw MW; Bhatti RA; Habibi H; McKiel CF; Guinan PD
Prostate; 1985; 7(2):151-9. PubMed ID: 4048013
[TBL] [Abstract][Full Text] [Related]
57. Differential response to 1,3-bis (2-chloroethyl)-1-nitrosourea in drug-resistant and -sensitive 9L rat brain tumor cells pretreated with alpha-difluoromethylornithine and 6-thioguanine.
Hunter KJ; Deen DF; Marton LJ
Int J Cancer; 1989 Oct; 44(4):658-60. PubMed ID: 2507451
[TBL] [Abstract][Full Text] [Related]
58. The effects of cyclophosphamide, ketoconazole, aclacinomycin-A, methotrexate, and scheduled methotrexate-5-fluorouracil combination chemotherapy on the transplantable R-3327 prostatic adenocarcinoma in the F1 hybrid male rat.
Smith JB; Ghayad PY; Dhabuwala CB; Drelichman A; Pierce JM
Cancer; 1985 Sep; 56(5):1045-8. PubMed ID: 3860279
[TBL] [Abstract][Full Text] [Related]
59. Novel therapy for the treatment of human carcinoid.
Evers BM; Hurlbut SC; Tyring SK; Townsend CM; Uchida T; Thompson JC
Ann Surg; 1991 May; 213(5):411-6. PubMed ID: 1708983
[TBL] [Abstract][Full Text] [Related]
60. Sustained delivery of difluoromethylornithine (DFMO) by means of implantable ceramic devices.
Benghuzzi HA; Bajpai PK
J Invest Surg; 1988; 1(3):163-70. PubMed ID: 3154094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
